SLPI, Human, ELISA kit

Catalog #: HK316-01
Quantity: 1 x 96 det.

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Secretory leukocyte proteinase inhibitor (SLPI; also known as antileukoprotease or ALP) is a 11.7 kDa cationic inhibitor of neutrophil elastase and to a lesser extent of cathepsin G. It is locally produced by epithelial cells in the lung, skin and other organs and by PMN and (in mice) by macrophages. In addition to its proteinase inhibitory properties that may serve to protect against proteolytic injury, it was recently shown that SLPI also displays several other functions such as antimicrobial and anti-inflammatory activities. These appear to be independent of its ability to inhibit PMN serine proteinases. SLPI has also been demonstrated to display antibacterial and antifungal activity at concentrations in which SLPI is present in mucosal secretions including those of the lung. Another possible role for SLPI is inhibition of protein disulphide isomerase that is considered essential for invasion of a cell by the Human Immunodeficiency Virus (HIV). Serum/plasma and urine of healthy individuals contains 50-80 ng/ml and 4 ng/ml respectively. Sputum of healthy individuals contains approximately 66 µg/ml.


Catalog number HK316-01
Product type Assays
Quantity 1 x 96 det.
Standard range 20-5,000 pg/ml
Detection level 20 pg/ml
Working volume 100 µl/well
Species Human
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least six months.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease Infectious diseases, Pulmonology
  • Application:
    The human SLPI ELISA kit is to be used for the in vitro quantitative determination of human SLPI in serum, plasma, urine, sputum, BALF and cell culture supernatant samples.
  • Principle:
    The human SLPI ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours. The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are captured by a solid bound specific antibody. Biotinylated tracer antibody will bind to captured human SLPI. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human SLPI standards (log). The human SLPI concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
1. Kramps, J et al; ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis 1984, 129: 959
2. Fahey, J et al; Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J Infect Dis 2002, 185: 1606
3. Devoogdt, N et al; Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. PNAS 2003, 100: 5778
4. Higashimoto, Y et al; Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells. Respiration 2005, 72: 629
5. Stock, S et al; Natural antimicrobial production by the amnion. Am J Obstet Gynecol 2007, 196: 255
6. Anderson, R et al; Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Eur Respir J 2008, 32: 670
7. López-Bermejo, A et al; The alarm secretory leukocyte protease inhibitor increases with progressive metabolic dysfunction. Clin Chim Acta 2011
You may also be interested in the following product(s)
Product description
Catalog #